Fiche publication
Date publication
mai 2024
Journal
Atherosclerosis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LESSINGER Jean-Marc
,
Pr SCHINI-KERTH Valérie
,
Dr AUGER Cyril
Tous les auteurs :
Matsushita K, Sato C, Bruckert C, Gong D, Amissi S, Hmadeh S, Fakih W, Remila L, Lessinger JM, Auger C, Jesel L, Ohlmann P, Kauffenstein G, Schini-Kerth VB, Morel O
Lien Pubmed
Résumé
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of cardiovascular events independently of glycemic control. However, the possibility that SGLT2 inhibitors improve vascular restenosis is unknown. The aim of this study was to examine whether dapagliflozin could prevent neointima thickening following balloon injury and, if so, to determine the underlying mechanisms.
Mots clés
Angiotensin, Dapagliflozin, Endothelial dysfunction, Neointima formation, Purinergic signaling, SGLT2
Référence
Atherosclerosis. 2024 05 23;:117595
